These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18157724)

  • 1. Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma.
    Hersey P; Halliday GM; Farrelly ML; DeSilva C; Lett M; Menzies SW
    Cancer Immunol Immunother; 2008 Jul; 57(7):1039-51. PubMed ID: 18157724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
    Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
    Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
    Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
    J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
    Ellebaek E; Engell-Noerregaard L; Iversen TZ; Froesig TM; Munir S; Hadrup SR; Andersen MH; Svane IM
    Cancer Immunol Immunother; 2012 Oct; 61(10):1791-804. PubMed ID: 22426890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
    Oshita C; Takikawa M; Kume A; Miyata H; Ashizawa T; Iizuka A; Kiyohara Y; Yoshikawa S; Tanosaki R; Yamazaki N; Yamamoto A; Takesako K; Yamaguchi K; Akiyama Y
    Oncol Rep; 2012 Oct; 28(4):1131-8. PubMed ID: 22895835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.
    Wilgenhof S; Corthals J; Van Nuffel AM; Benteyn D; Heirman C; Bonehill A; Thielemans K; Neyns B
    Cancer Immunol Immunother; 2015 Mar; 64(3):381-8. PubMed ID: 25548092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
    Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T
    Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
    Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
    Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
    Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
    Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.
    von Euw EM; Barrio MM; Furman D; Levy EM; Bianchini M; Peguillet I; Lantz O; Vellice A; Kohan A; Chacón M; Yee C; Wainstok R; Mordoh J
    J Transl Med; 2008 Jan; 6():6. PubMed ID: 18221542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
    Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
    Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.
    Carreno BM; Becker-Hapak M; Huang A; Chan M; Alyasiry A; Lie WR; Aft RL; Cornelius LA; Trinkaus KM; Linette GP
    J Clin Invest; 2013 Aug; 123(8):3383-94. PubMed ID: 23867552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells.
    Mackensen A; Herbst B; Chen JL; Köhler G; Noppen C; Herr W; Spagnoli GC; Cerundolo V; Lindemann A
    Int J Cancer; 2000 May; 86(3):385-92. PubMed ID: 10760827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
    O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
    Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.